(Q43584066)

24 November 2017

title

Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia (English)

1 reference

24 November 2017

0 references

1 reference

3

1 reference

24 November 2017

7

1 reference

24 November 2017

Rachel Sacks-Davis

5

0 references

Peter Vickerman

object named as

Peter Vickerman

8

0 references

Margaret E Hellard

1

object named as

Margaret E Hellard

1 reference

24 November 2017

Rebecca Jenkinson

2

1 reference

24 November 2017

Mark A Stoové

4

1 reference

24 November 2017

Judy Gold

6

1 reference

24 November 2017

Natasha K Martin

9

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 June 2012

1 reference

Medical Journal of Australia

24 November 2017

published in

1 reference

24 November 2017

volume

196

1 reference

24 November 2017

issue

10

1 reference

24 November 2017

page(s)

638-641

1 reference

Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility

24 November 2017

cites work

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997-2006.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

High incidence of hepatitis C virus reinfection in a cohort of injecting drug users

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

Mathematical modelling of hepatitis C treatment for injecting drug users

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

Hepatitis C virus genotypes in Australia

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

Global epidemiology of hepatitis C virus infection

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

Will interferon-free regimens prevail?

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

Hepatitis C prevention and treatment for substance users in the United States: acknowledging the elephant in the living room

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy?

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

Global estimates of prevalence of HCV infection among injecting drug users.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

Telaprevir for previously treated chronic HCV infection

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

Hepatitis C treatment for injection drug users: a review of the available evidence

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

Mortality among injecting drug users in Melbourne: a 16-year follow-up of the Victorian Injecting Cohort Study (VICS).

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.5694/MJA11.10981

Identifiers

DOI

10.5694/MJA11.10981

1 reference

24 November 2017

1 reference